Saxenda is a daily subcutaneous injection of liraglutide 3.0 mg, FDA-approved for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition, and in adolescents 12 to 17 years old with a BMI in the 95th percentile or above. Saxenda belongs to the GLP-1 receptor agonist class. This guide covers the side-effect profile in detail — what the clinical trials showed, how to manage common symptoms, and which signs require urgent attention.
Why Saxenda Causes Side Effects
Liraglutide is a GLP-1 receptor agonist that activates receptors in the gut, pancreas, and brain. The same mechanisms that drive weight loss — slowed gastric emptying, suppressed appetite, reduced hunger signaling — also cause many of the side effects, particularly the gastrointestinal symptoms. Saxenda is dosed at 3.0 mg daily, which is roughly 1.7 times the maximum Victoza dose (1.8 mg for type 2 diabetes), so side effect rates are somewhat higher than for liraglutide at the diabetes dose.
Common Side Effects from the SCALE Trial
| Side Effect | Saxenda Frequency | Placebo Frequency |
|---|---|---|
| Nausea | about 39 percent | about 14 percent |
| Diarrhea | about 20 percent | about 9 percent |
| Constipation | about 19 percent | about 9 percent |
| Vomiting | about 16 percent | about 4 percent |
| Headache | about 14 percent | about 12 percent |
| Decreased appetite | about 10 percent | about 2 percent |
| Dyspepsia (indigestion) | about 10 percent | about 3 percent |
| Fatigue | about 8 percent | about 4 percent |
| Dizziness | about 7 percent | about 4 percent |
| Abdominal pain | about 5 percent | about 3 percent |
| Injection site reactions | about 14 percent | about 11 percent |
| Hypoglycemia (in T2D users on insulin/SU) | up to 40 percent | about 16 percent |
Dose Escalation Schedule to Reduce Side Effects
| Week | Daily Dose | Purpose |
|---|---|---|
| Week 1 | 0.6 mg | Tolerance-building |
| Week 2 | 1.2 mg | Continued titration |
| Week 3 | 1.8 mg | Equivalent to maximum Victoza dose |
| Week 4 | 2.4 mg | Final step before maintenance |
| Week 5 onward | 3.0 mg | Maintenance dose for weight management |
If a step is poorly tolerated, the manufacturer recommends pausing escalation for an additional week before moving up. If 3.0 mg cannot be tolerated, the medication should be discontinued — chronic weight management approval is specifically at the 3.0 mg dose.
How to Manage Nausea
- Eat smaller meals — half the usual portion is often the right starting point
- Eat slowly and stop at first fullness — Saxenda makes the stomach empty more slowly, so you fill up sooner
- Avoid high-fat, fried, and very spicy foods, particularly in the first weeks
- Avoid alcohol, which worsens nausea and may compound dehydration risk
- Drink small sips of water throughout the day rather than large volumes at once
- Ginger tea, peppermint, or carbonated water can help mild nausea
- OTC anti-nausea options (meclizine, dimenhydrinate) can be used short-term; ask your clinician first
- Prescription antiemetics (ondansetron) may be appropriate for severe symptoms
- Inject in the evening if morning nausea is the dominant problem (or vice versa)
How to Manage Diarrhea and Constipation
- For diarrhea: Stay hydrated with water and electrolyte drinks. Eat simple foods (rice, toast, banana) and avoid sugar alcohols (sorbitol, xylitol), high-fat meals, and large dairy portions. Short-term loperamide may help; check with your clinician.
- For constipation: Increase fluids and gradually add fiber (chia, ground flax, psyllium, oat bran). Daily light activity matters more than people expect. A magnesium citrate or oxide supplement can help; ask your pharmacist.
Serious Side Effects — When to Seek Care
- Acute pancreatitis. Severe persistent abdominal pain, often radiating to the back, with nausea and vomiting. Stop Saxenda and seek urgent evaluation.
- Gallbladder disease. Right upper abdominal pain, especially after meals, with nausea, fever, or yellowing of skin. Rapid weight loss raises gallstone risk regardless of medication.
- Acute kidney injury. Decreased urine output, swelling, fatigue, confusion — often triggered by dehydration from severe vomiting or diarrhea. Stop the medication and seek care.
- Hypoglycemia. Particularly if also taking insulin or a sulfonylurea. Symptoms include shakiness, sweating, confusion, hunger, dizziness. The diabetes medication dose often needs to be reduced when starting Saxenda.
- Suicidal ideation or mood changes. The FDA label notes a small signal for suicidal thoughts in patients taking weight management drugs; monitor for new or worsening depression or thoughts of self-harm.
- Allergic reaction. Rash, itching, swelling of face or throat, breathing difficulty. Seek emergency care.
- Heart rate increase. Liraglutide can raise resting heart rate by 2 to 3 beats per minute on average; report palpitations or rapid heartbeat.
- Diabetic retinopathy progression. Monitor with eye exams if you have type 2 diabetes and existing retinopathy.
Boxed Warning — Thyroid C-Cell Tumors
Saxenda carries an FDA boxed warning based on rodent studies in which liraglutide and other GLP-1 receptor agonists caused thyroid C-cell tumors. Whether this occurs in humans is unknown — population data have not shown a clear elevated risk, but the warning remains. Saxenda is contraindicated in people with:
- A personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
If you develop new neck swelling, hoarseness, difficulty swallowing, or persistent shortness of breath, contact your clinician for evaluation.
Injection Site Reactions
Saxenda is a daily subcutaneous injection. Site reactions occur in roughly 14 percent of users and typically include redness, mild swelling, itching, or a small bruise that resolves within a week.
- Rotate between the abdomen, front of thigh, and back of upper arm
- Move at least 1 inch from the previous injection site each day
- Warm the pen to room temperature for 15 to 30 minutes before injection to reduce stinging
- Use a fresh needle each time
- Inject perpendicular to the skin (90 degrees)
- Do not rub the site afterward
Side Effect Timeline
- Week 1 (0.6 mg). Mild nausea, possible appetite reduction. Site reactions possible.
- Weeks 2 to 3 (1.2 to 1.8 mg). Nausea may intensify; usually peaks in this window.
- Week 4 to 5 (2.4 to 3.0 mg). Some users feel another wave of nausea; others tolerate the increase well.
- Weeks 6 to 12. Side effects gradually settle. Weight loss of 4 to 8 percent is typical by week 12.
- Months 4 to 12. Maintenance phase. Most users report minimal side effects. Continue regular check-ins.
Side Effects That Mean Stop the Medication
- Anaphylaxis (face, lip, throat swelling, breathing difficulty)
- Acute pancreatitis confirmed clinically or on imaging
- Symptomatic gallbladder disease requiring intervention
- Severe persistent vomiting causing dehydration and kidney injury
- Persistent intolerable nausea after 12 weeks at maintenance dose despite management
- New medullary thyroid carcinoma symptoms (neck mass, hoarseness, dysphagia)
- Worsening depression or suicidal ideation
Saxenda vs Victoza — Same Drug, Different Doses
Saxenda and Victoza are both brand names for liraglutide. Saxenda is dosed up to 3.0 mg daily for chronic weight management; Victoza is dosed up to 1.8 mg daily for type 2 diabetes. Higher doses produce greater weight loss and somewhat higher side-effect rates. The molecule is identical.
Related Reading
For more on this medication and related options, see our guides on Saxenda for weight loss, Saxenda versus Victoza, Victoza for type 2 diabetes, and our broader treatment options hub. For context on glucose targets in users with type 2 diabetes, see our A1C levels guide. The full FDA-approved Saxenda prescribing information is the authoritative source on side effects and contraindications.
The Bottom Line
Saxenda side effects are mostly gastrointestinal — nausea, diarrhea, constipation, vomiting, and decreased appetite — with frequencies that drop substantially after the 5-week dose escalation. Serious risks include acute pancreatitis, gallbladder events, acute kidney injury from dehydration, and a boxed thyroid C-cell tumor warning. Most users find side effects tolerable with small-meal strategies, hydration, and slow titration. Severe persistent symptoms, signs of pancreatitis, or gallbladder pain require urgent evaluation. Talk to your clinician about whether the side-effect profile fits your situation.
